Developing aptamers into therapeutics.
暂无分享,去创建一个
[1] J. Nevins,et al. Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function , 1996, Nature Medicine.
[2] C. Vargeese,et al. Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. , 1995, Biochemistry.
[3] Wei-xing Li,et al. A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. , 1994, Blood.
[4] Sheela M. Waugh,et al. 2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.
[5] C. Heldin,et al. Intimal Hyperplasia Recurs After Removal of PDGF-AB and -BB Inhibition in the Rat Carotid Artery Injury Model , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[6] A. DeAnda,et al. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. , 1994, The Annals of thoracic surgery.
[7] J. Doudna,et al. Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[8] D. Williams,et al. 2'-Fluoro- and 2'-amino-2'-deoxynucleoside 5'-triphosphates as substrates for T7 RNA polymerase. , 1992, Biochemistry.
[9] J. Szostak,et al. In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.
[10] L. Gold,et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.
[11] N. Usman,et al. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. , 2000, The Journal of clinical investigation.
[12] M Yarus,et al. Diversity of oligonucleotide functions. , 1995, Annual review of biochemistry.
[13] T. Ogihara,et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[14] C. Salata,et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. , 1999, Blood.
[15] C H Heldin,et al. Inhibitory DNA ligands to platelet-derived growth factor B-chain. , 1996, Biochemistry.
[16] Eli Gilboa,et al. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication , 1990, Cell.
[17] J. Rapp. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF , 1993 .
[18] M. Mann,et al. Therapeutic applications of transcription factor decoy oligonucleotides. , 2000, The Journal of clinical investigation.
[19] T. Lee,et al. Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication , 1990, Molecular and cellular biology.
[20] F. Eckstein,et al. Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. , 1991, Science.
[21] S. Srinivasan,et al. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides , 1995, Journal of clinical laboratory analysis.
[22] B. Sullenger,et al. Blocking the Initiation of Coagulation by RNA Aptamers to Factor VIIa , 2000, Thrombosis and Haemostasis.
[23] E. Vermaas,et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin , 1992, Nature.
[24] T. Zhang,et al. Liposome-anchored vascular endothelial growth factor aptamers. , 1998, Bioconjugate chemistry.
[25] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[26] J. Polak,et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial , 1999, The Lancet.
[27] A D Ellington,et al. Isozyme-specific inhibition of protein kinase C by RNA aptamers. , 1994, The Journal of biological chemistry.
[28] A. Karpeisky,et al. Chemical Modification of Hammerhead Ribozymes , 1995, The Journal of Biological Chemistry.
[29] N. Janjić,et al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. , 1999, The American journal of pathology.
[30] L. Khachigian,et al. Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. , 2000, The Journal of clinical investigation.
[31] S. Gill,et al. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. , 1999, Journal of chromatography. B, Biomedical sciences and applications.
[32] B. Sullenger,et al. Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies , 1997, Nature Biotechnology.
[33] N. Janjić,et al. VEGF(165) mediates glomerular endothelial repair. , 1999, The Journal of clinical investigation.
[34] L. C. Bock,et al. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. , 1993, Blood.